Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221077 | 0.85 | ALDH1A1 (0.57) | ALDH1A1CYP3A4CTSBERN1S100A4 | |
| SCHEMBL11749582 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CTSBXDHPARP1 | |
| SCHEMBL7032612 | 0.80 | ALDH1A1 (0.63) | ALDH1A1CYP3A4XDHLMNATDP1 | |
| SCHEMBL1281710 | 0.79 | ALDH1A1 (0.56) | ALDH1A1CYP3A4CTSBERN1S100A4 | |
| SCHEMBL2783704 | 0.79 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CTSBERN1S100A4 | |
| SCHEMBL29706644 | 0.79 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CTSBERN1S100A4 | |
| SCHEMBL4704860 | 0.78 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CTSBXDHPARP1 | |
| SCHEMBL17770642 | 0.78 | CYP1A2 (0.52) | ALDH1A1CYP3A4ERN1S100A4TRPV1 | |
| SCHEMBL3011561 | 0.78 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CTSBXDHPARP1 | |
| SCHEMBL31423032 | 0.78 | CYP1A2 (0.52) | ALDH1A1CYP3A4ERN1S100A4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4656629-A1 | INDOLE DERIVATIVE WITH SUBSTITUENT AND PHARMACEUTICAL USE | MitoImmune Therapeutics Inc. (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4097099-B9 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119874775-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119841865-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119823184-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4524135-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-03-19 | — | — | EP | disclosed |
| CN-119212988-A | Kinesin KIF18A inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119143752-A | Aminoquinoline derivative, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| CN-101472585-A | Antibacterial compositions | PROLYSIS LTD (GB) | 2009-07-01 | — | — | CN | disclosed |
| EP-2034997-A1 | ANTIBACTERIAL COMPOSITIONS | Prolysis Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007148093-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD. (GB) | 2007-12-27 | — | — | WO | disclosed |
| US-4053527-A | REACTING HALONITROANILINES WITH ALCOHOLS AND NITROSATING AGENTS ION | BASF AKTIENGESELLSCHAFT (DT) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | ALDH1A1 238/4885CYP3A4 3671/4885CTSB 460/4885 |
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | ALDH1A1 3469/4885CYP3A4 849/4885CTSB 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.